The Technical Analyst
ACADIA Pharmaceuticals [ACAD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ACADIA Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.90% $16.59
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 733.57 mill |
| EPS: | -0.370 |
| P/E: | -44.84 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 164.77 mill |
| Avg Daily Volume: | 1.804 mill |
| RATING 2024-04-23 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -44.84 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -7.63x |
| Company: PE -44.84 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 15.79 - 17.40 ( +/- 4.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Thompson Elizabeth H.z. | Buy | 0 | |
| 2024-04-05 | Davis Stephen | Buy | 34 666 | Common Stock |
| 2024-04-08 | Davis Stephen | Sell | 8 858 | Common Stock |
| 2024-04-08 | Davis Stephen | Sell | 17 716 | Common Stock |
| 2024-04-05 | Davis Stephen | Sell | 34 666 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 31.73 |
| Last 98 transactions |
| Buy: 1 174 699 | Sell: 709 800 |
Forecast:
16:00 - $16.57
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.57
Forecast 2: 16:00 - $16.57
Forecast 3: 16:00 - $16.57
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.59 (-0.90% ) |
| Volume | 1.064 mill |
| Avg. Vol. | 1.804 mill |
| % of Avg. Vol | 58.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACAD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.56 | N/A | Active |
|---|
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-22 09:04:00 - Press Release
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Has Been Accepted For Filing And Priority Review By Health Canada
San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that health canada has accepted its new drug submission (nds) for trofinetide for the treatment of rett syndrome, a rare neurodevelopmental disorder. health canada has granted priority review for acadia's submission. “rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said pamela di c.
2024-04-19 16:05:00 - Press Release
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that on april 10, 2024, the compensation committee of acadia's board of directors (the “committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“rsus”) to six new employees under acadia's 2023 inducement plan. the compensation committee approved the awards as an inducement material to the new employees' employ.
2024-04-17 16:05:00 - Press Release
Acadia Pharmaceuticals Presents New Daybue™ (trofinetide) Clinical Data At The 2024 American Academy Of Neurology (aan) Annual Meeting
San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that two oral presentations featuring daybue™ (trofinetide) findings in rett syndrome will be presented at the american academy of neurology (aan) 2024 annual meeting, being held this week in denver, co. the presentations include outcomes from the daffodil™, a phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of daybue in girls aged two to four living with rett syndrome,.
2024-04-05 07:00:00 - Press Release
Investigation Alert: The Schall Law Firm Announces It Is Investigating Claims Against Acadia Pharmaceuticals Inc. And Encourages Investors With Losses To Contact The Firm
Los angeles, ca / accesswire / april 5, 2024 / the schall law firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of acadia pharmaceuticals inc. ("acadia" or "the company") (nasdaq:acad) for violations of the securities laws. the investigation focuses on whether the company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
2024-04-02 16:05:00 - Press Release
Acadia Appoints Elizabeth H. Z. Thompson, Ph.d.
San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced the appointment of dr. elizabeth h. z. thompson as executive vice president, head of research and development. dr. thompson will lead research and development at acadia and serve as a member of the company's executive leadership team, reporting to steve davis, chief executive officer of acadia. “liz is a preeminent drug research and development leader with extensive experience in the advancement and commercia.
Latest News
2024-04-11 14:10:34 - InvestorPlace
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
2024-03-12 15:20:55 - Investopedia
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
2024-03-12 12:11:05 - Zacks Investment Research
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
2024-03-12 10:46:41 - InvestorPlace
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
2024-03-12 09:30:30 - InvestorPlace
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
2024-03-11 17:01:00 - Market Watch
Acadia Pharma's stock falls 15% after failed drug trial
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
2024-02-28 10:15:27 - Zacks Investment Research
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
2024-02-27 18:21:09 - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
2024-02-20 11:06:37 - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-15 11:35:29 - Reuters
Culper Research takes short position in Acadia Pharma
Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.